Dec 1, 2022 5:03pm EST Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Nov 10, 2022 4:05pm EST Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
